These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32045689)

  • 1. Development and in vitro evaluation of a new adjuvant system containing Salmonella Typhi porins and chitosan.
    Yüksel S; Pekcan M; Puralı N; Esendağlı G; Tavukçuoğlu E; Rivero-Arredondo V; Ontiveros-Padilla L; López-Macías C; Şenel S
    Int J Pharm; 2020 Mar; 578():119129. PubMed ID: 32045689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo evaluation of new adjuvant systems based on combination of Salmonella Typhi porins with particulate systems: Liposomes versus polymeric particles.
    Parmaksız S; Pekcan M; Özkul A; Türkmen E; Rivero-Arredondo V; Ontiveros-Padilla L; Forbes N; Perrie Y; López-Macías C; Şenel S
    Int J Pharm; 2023 Dec; 648():123568. PubMed ID: 37925042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucan Particles Are a Powerful Adjuvant for the HBsAg, Favoring Antiviral Immunity.
    Soares E; Groothuismink ZMA; Boonstra A; Borges O
    Mol Pharm; 2019 May; 16(5):1971-1981. PubMed ID: 30964694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
    Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
    Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salmonella Typhi OmpS1 and OmpS2 porins are potent protective immunogens with adjuvant properties.
    Moreno-Eutimio MA; Tenorio-Calvo A; Pastelin-Palacios R; Perez-Shibayama C; Gil-Cruz C; López-Santiago R; Baeza I; Fernández-Mora M; Bonifaz L; Isibasi A; Calva E; López-Macías C
    Immunology; 2013 Aug; 139(4):459-71. PubMed ID: 23432484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of multistage recombinant protein vaccine formulations against toxoplasmosis using a new chitosan and porin based adjuvant system.
    Parmaksız S; Gül A; Erkunt Alak S; Karakavuk M; Can H; Gül C; Karakavuk T; López-Macías C; Puralı N; Döşkaya M; Şenel S
    Int J Pharm; 2022 Oct; 626():122199. PubMed ID: 36115468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cationic polymer modified PLGA nanoparticles encapsulating Alhagi honey polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses.
    Wusiman A; Gu P; Liu Z; Xu S; Zhang Y; Hu Y; Liu J; Wang D; Huang X
    Int J Nanomedicine; 2019; 14():3221-3234. PubMed ID: 31123399
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    Bento D; Staats HF; Gonçalves T; Borges O
    Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and physicochemical, toxicity and immunogenicity assessments of recombinant hepatitis B surface antigen (rHBsAg) entrapped in chitosan and mannosylated chitosan nanoparticles: as a novel vaccine delivery system and adjuvant.
    Mehrabi M; Dounighi NM; Rezayat Sorkhabadi SM; Doroud D; Amani A; Khoobi M; Ajdary S; Pilehvar-Soltanahmadi Y
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):230-240. PubMed ID: 29260901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acidified sucralfate encapsulated chitosan derivative nanoparticles as oral vaccine adjuvant delivery enhancing mucosal and systemic immunity.
    Zhao Z; Qiao S; Jin Z; Li H; Yu H; Zhang C; Yin TH; Zhao K
    Int J Biol Macromol; 2024 Nov; 279(Pt 3):135424. PubMed ID: 39245128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunopotentiator-Loaded Polymeric Microparticles as Robust Adjuvant to Improve Vaccine Efficacy.
    Zhang W; Wang L; Yang T; Liu Y; Chen X; Liu Q; Jia J; Ma G
    Pharm Res; 2015 Sep; 32(9):2837-50. PubMed ID: 26017300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving adjuvanticity of quaternized chitosan-based microgels for H5N1 split vaccine by tailoring the particle properties to achieve antigen dose sparing effect.
    Wang YQ; Fan QZ; Liu Y; Yue H; Ma XW; Wu J; Ma GH; Su ZG
    Int J Pharm; 2016 Dec; 515(1-2):84-93. PubMed ID: 27697632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced mucosal immune responses against tetanus toxoid using novel delivery system comprised of chitosan-functionalized gold nanoparticles and botanical adjuvant: characterization, immunogenicity, and stability assessment.
    Barhate G; Gautam M; Gairola S; Jadhav S; Pokharkar V
    J Pharm Sci; 2014 Nov; 103(11):3448-3456. PubMed ID: 25219511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are chitosan natural polymers suitable as adjuvant/delivery system for anti-tuberculosis vaccines?
    Khademi F; Taheri RA; Yousefi Avarvand A; Vaez H; Momtazi-Borojeni AA; Soleimanpour S
    Microb Pathog; 2018 Aug; 121():218-223. PubMed ID: 29800697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunostimulatory effect of chitosan and quaternary chitosan: A review of potential vaccine adjuvants.
    Li X; Xing R; Xu C; Liu S; Qin Y; Li K; Yu H; Li P
    Carbohydr Polym; 2021 Jul; 264():118050. PubMed ID: 33910752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly-ϵ-caprolactone/chitosan nanoparticles provide strong adjuvant effect for hepatitis B antigen.
    Jesus S; Soares E; Borchard G; Borges O
    Nanomedicine (Lond); 2017 Oct; 12(19):2335-2348. PubMed ID: 28868964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances on chitosan as an adjuvant for vaccine delivery.
    Dmour I; Islam N
    Int J Biol Macromol; 2022 Mar; 200():498-519. PubMed ID: 34973993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chitosan derivative composite nanoparticles as adjuvants enhance the cellular immune response via activation of the cGAS-STING pathway.
    Zhao Z; Peng Y; Shi X; Zhao K
    Int J Pharm; 2023 Apr; 636():122847. PubMed ID: 36933583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
    Pawar D; Mangal S; Goswami R; Jaganathan KS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Conjugated Chitosan-Based Nanoparticles to Proteic Antigens Elicit Similar Humoral Immune Responses to Those Obtained with Alum.
    Izaguirre-Hernández IY; Mellado-Sánchez G; Mondragón-Vásquez K; Thomas-Dupont P; Sánchez-Vargas LA; Hernández-Flores KG; Mendoza-Barrera C; Altuzar V; Cedillo-Barrón L; Hernández-Flores KG; Mendoza-Barrera C; Altuzar V; Cedillo-Barrón L; Vivanco-Cid H
    J Nanosci Nanotechnol; 2017 Jan; 17(1):846-52. PubMed ID: 29634187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.